<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>虚拟细胞 on AI内参</title>
    <link>https://www.neican.ai/tags/%E8%99%9A%E6%8B%9F%E7%BB%86%E8%83%9E/</link>
    <description>Recent content in 虚拟细胞 on AI内参</description>
    <generator>Hugo</generator>
    <language>zh-cn</language>
    <lastBuildDate>Tue, 07 Jul 2026 09:40:12 +0800</lastBuildDate>
    <atom:link href="https://www.neican.ai/tags/%E8%99%9A%E6%8B%9F%E7%BB%86%E8%83%9E/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>虚拟细胞：在数字实验室里为药物“预演”生死</title>
      <link>https://www.neican.ai/insights/article-20260707094012026-1/</link>
      <pubDate>Tue, 07 Jul 2026 09:40:12 +0800</pubDate>
      <guid>https://www.neican.ai/insights/article-20260707094012026-1/</guid>
      <description>华源智因凭借虚拟细胞技术将AI制药从静态靶点发现推向动态人体药效预测，通过与医疗机构合作建立数据壁垒，展现了AI在降低新药研发“双十”失败风险中的显著商业价值。这一技术路径不仅推动了生物医药的数字化转型，也预示着AI制药正迈向以临床实效为中心的精准研发新阶段。</description>
    </item>
  </channel>
</rss>
